脂质体布比卡因在接受后路器械融合术的青少年特发性脊柱侧凸患儿中的疼痛控制疗效
回顾性队列研究纳入2018至2024年472例接受后路脊柱融合术的青少年特发性脊柱侧凸患儿,比较术中切口周围注射脂质体布比卡因(LB组295例)与未注射(N-LB组177例)的围手术期疼痛结局。LB组术后第1天、第2天及总体静息疼痛评分显著更低,住院时间更短,术后0天离床比例更高,术后0至24小时及总住院期间阿片类药物消耗更少,并发症未增加。
要点
- LB组术后第1天、第2天及总体静息疼痛评分显著低于N-LB组(P<0.05)。
- LB组住院时间显著短于N-LB组(P<0.001),术后0天离床比例59.9% vs 38.0%(P<0.001)。
- LB组术后0至24小时及总住院阿片类药物消耗显著更少(P<0.001和P=0.032),并发症未增加。
核心结论
- 接受脂质体布比卡因的患儿静息VAS疼痛评分更低、阿片类药物消耗更少、住院时间更短,且并发症未增加。
- 作者认为长效局麻药制剂可能提供更优的疼痛管理。
研究设计与样本
- 回顾性队列研究,纳入2018至2024年间472例接受后路脊柱融合术的脊柱畸形患儿。
- 自2018年初起,部分患者在关切口时由整形外科医生行切口周围脂质体布比卡因注射(LB组295例),与未接受任何注射者(N-LB组177例)比较。
- 采用Wilcoxon秩和检验比较连续变量,采用χ²检验或Fisher精确检验比较分类变量,并采用非参数协方差分析比较术后第1天和第2天静息疼痛评分及吗啡消耗量。
主要发现
- LB组与N-LB组人口学特征无差异。
- LB组术后第1天、第2天及总体静息疼痛评分显著低于N-LB组(P<0.05)。
- LB组住院时间显著短于N-LB组(P<0.001)。
- LB组术后0天离床患者比例显著高于N-LB组(59.9% vs 38.0%,P<0.001)。
- LB组术后0至24小时及总住院期间阿片类药物消耗显著少于N-LB组(P<0.001和P=0.032)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Retrospective cohort study. OBJECTIVE: This study aimed to compare perioperative pain outcomes in adolescent idiopathic scoliosis (AIS) patients who either did or did not receive a liposomal bupivacaine (LB) injection during their posterior spinal fusion (PSF). SUMMARY OF BACKGROUND DATA: Liposomal bupivacaine (LB) has been promoted for its apparent long-lasting effects on pain management when compared with standard formulations. Many studies in adult spine populations have been carried out with varying results but few studies have investigated LB's effect in the pediatric population. METHODS: Four hundred seventy-two pediatric patients with spine deformity undergoing posterior spinal fusion (PSF) between 2018 and 2024 were included. Starting early 2018, patients began receiving peri-incisional injections of LB by plastic surgeons during PSF closure (LB group). These patients were compared with those that did not receive any injections [Non-LB [N-LB] group]. Pain scores, opioid consumption (MME), time to ambulation (out-of-bed/OOB), length of stay (LOS), narcotic refills, and 90-day complications were analyzed. Differences between the LB and N-LB groups were assessed using the Wilcoxon rank-sum test for continuous variables and either the χ 2 test or Fisher exact test for categorical variables, as appropriate. A nonparametric analysis of covariance (ANCOVA) was conducted to compare pain scores at rest on POD1 and POD2, as well as morphine consumption during the first 24 hours and total morphine consumption. RESULTS: Two hundred ninety-five patients were in the LB Group, and 177 patients were N-LB. No differences were noted in demographics. Pain scores at rest were significantly lower on POD 1, POD 2, and overall ( P <0.05) in LB patients. LOS was significantly shorter in LB patients ( P <0.001). Significantly more patients were out of bed by POD 0 (59.9% vs. 38.0%, P <0.001) in the LB group. LB patients consumed significantly less opioids in 0 to 24 hours postop and during their total hospital stay ( P <0.001 and P =0.032, respectively). CONCLUSIONS: Patients who received liposomal bupivacaine had lower VAS pain scores at rest, opioid consumption, and length of stay with no increase in complications. This suggests that a long-acting local anesthetic formulation may offer superior pain management.
引用
- Sarwahi V, Morledge A, Cohen A, et al. Efficacy of Liposomal Bupivacaine for Pain Control in Pediatric Patients With Adolescent Idiopathic Scoliosis Undergoing Instrumented Posterior Spinal Fusion. Spine (Phila Pa 1976). 2025. PMID: 41150701. doi:10.1097/BRS.0000000000005548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。